/o/p/x/a/ probably see mid $3's imo.
Steady accumulation now/
Cancer and Multiple Sclerosis. Both are grossly undervalued which is a very nice surprise.
This little biotech may triple soon. Now at just .50
Their is word that a phama co is looking to acquire little DARA Bio so keep an eye on it.
New filing reveals Merck's knowledge of favorable status for the Tcelna Phase 2b from their increased cash commitment to Opexa.
When Opexa announces their update, which is likely to be preceded by another commitment from Merck (specifically Serono), then the pps will more fairly valued in the $6-7 range.